1. CD24+CD44+CD54+EpCAM+ gastric cancer stem cells predict tumor progression and metastasis: clinical and experimental evidence
- Author
-
Angel A. Gómez-Gallegos, Lizbeth Ramírez-Vidal, Jared Becerril-Rico, Elizabeth Pérez-Islas, Zuly J. Hernandez-Peralta, Mariel E. Toledo-Guzmán, Alejandro García-Carrancá, Elizabeth Langley, Angélica Hernández-Guerrero, Fernando López-Casillas, Roberto Herrera-Goepfert, Luis F. Oñate-Ocaña, and Elizabeth Ortiz-Sánchez
- Subjects
Gastric cancer ,Cancer stem cells ,Immunophenotype ,Metastasis ,Zebrafish ,Xenotransplants ,Medicine (General) ,R5-920 ,Biochemistry ,QD415-436 - Abstract
Abstract Background Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide. Specific and thorough identification of cancer cell subsets with higher tumorigenicity and chemoresistance, such as cancer stem cells (CSCs), could lead to the development of new and promising therapeutic targets. For better CSC identification, a complete or extended surface marker phenotype is needed to provide increased specificity for new cell targeting approaches. Our goal is to identify and characterize a putative extended phenotype for CSCs derived from patients with GC before treatment, as well as to evaluate its clinical value. In addition, we aim to ensure that cells with this phenotype have stemness and self-renewal capabilities. Methods This is a cohort study including 127 treatment-naïve patients with GC who attended the Instituto Nacional de Cancerología. Multiparametric flow cytometry analysis was performed to determine the extended phenotype of cells derived from gastric biopsies. The tumorigenic capability of cells identified in patients was assessed in a zebrafish model. Results CD24+CD44+CD54+EpCAM+ cells were present in all treatment-naïve patients included, with a median abundance of 1.16% (0.57–1.89%). The percentage of CD24+CD44+CD54+EpCAM+ cells was categorized as high or low using 1.19% as the cutoff for the CD24+CD44+CD54+EpCAM+ cell subset. Additionally, a higher TNM stage correlated with a higher percentage of CD24+CD44+CD54+EpCAM+ cells (Rho coefficient 0.369; p
- Published
- 2023
- Full Text
- View/download PDF